Priorities on Dealing with the 'Big Three' Infectious Diseases: HIV/AIDS, Tuberculosis and Malaria

Article

David Molyneux, a professor at the the Liverpool School of Tropical Medicine, Liverpool, England, outlines how priorities on dealing with the big 3 infectious diseases -- HIV/AIDS, tuberculosis, and malaria -- is obstructing public health initiatives to tackle preventable diseases such as the viral, bacterial, and parasitic infections of the tropics, and acute respiratory infections and diarrheal diseases of children. Examples are given of numerous cost-effective treatment programs for diseases such as onchocerciasis (river blindness) and Chagas disease.

Molyneux comments, The emphasis on the 'Big Three' killers and the derogatory assignment to the category of other diseases of those that can so easily be controlled or even eliminated, neglects the proven success of a range of interventions. An investment of a fraction of the annual requirements of the global fund would bring long-lasting benefit to the millions that still remain disabled, reduce morbidity, and prevent disablement in future generations. If we are to ensure the efficient use of the substantial resources needed to reduce morbidity and mortality associated with HIV/AIDS, tuberculosis, and malaria, then a small investment in proven, cost-effective interventions against other diseases -- preferably from the global fund resources -- will bring sustainable public-health benefits, integrate well with and strengthen the health system, reduce disabling conditions, and bring collateral benefits to the health of the poorest nations.

He concludes, Policy makers are ignoring scientific and operational evidence that interventions against other diseases are effective. By concentrating on so few agents, current policies could perpetuate inequity, disrupt health financing policies, divert human resources from achievable goals, and deny opportunities for impoverished health systems to improve. Current policy also raises ethical issues. Resources are being transferred to interventions against the 'Big Three'  that, realistically, have only a limited chance of success as they are reactive and do not adequately control transmission -- a pre-requisite for any public-health impact.

Source: Liverpool School of Tropical Medicine

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
David J. Weber, MD, MPH, president of the Society for Healthcare Epidemiology of America
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
© 2025 MJH Life Sciences

All rights reserved.